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Objective: The objective of this study was to examine the feasibility of
human interleukin 10 gene transfer into rat lung isografts and to investigate
the effect of gene transfer on subsequent ischemia-reperfusion injury.
Methods: Male F344 rats were divided into 4 groups and underwent left lung
isotransplantation. Twenty-four hours before harvest, 5 × 10E9 pfu (group I,
n = 6) or 1 × 10E10 pfu (group II, n = 7) of AdRSVhIL-10 was intravenous-
ly administered to donor rats. In group I-C (n = 6) and group II-C (n = 6),
serving as controls, 5 × 10E9 pfu and 1 × 10E10 pfu of AdCMVLacZ were
administered, respectively. Grafts were preserved for 18 hours at 4°C before
implantation and assessed 24 hours after reperfusion. Transgene expression
of human interleukin 10 was assessed by both reverse transcriptase–poly-
merase chain reaction and immunohistochemistry. Graft inducible nitric
oxide synthase, tumor necrosis factor α, intercellular adhesion molecule-1,
growth-regulated gene product/cytokine-induced neutrophil chemoattrac-
tant-1, and monocyte chemotactic protein-1 mRNA expression were
assessed by reverse transcriptase–polymerase chain reaction. Isograft gas
exchange, exhaled nitric oxide, and myeloperoxidase activity were also ana-
lyzed.
Results: Dose-dependent transgene expression was detected by reverse tran-
scriptase–polymerase chain reaction and immunohistochemistry. Arterial
PO2 in groups I (164.72 ± 85.3 mm Hg) and II (153.19 ± 113 mm Hg) was
significantly higher than in groups I-C (82.37 ± 19.1 mm Hg) and II-C
(77.95 ± 33.4 mm Hg) (P = .022 and P = .031, respectively). Arterial PCO2
in group I (33.40 ± 6.80 mm Hg) was significantly lower than in group I-C
(51.23 ± 11.9 mm Hg) (P = .0096). Myeloperoxidase activity in group II
(0.083 ± 0.031 ∆OD · min–1 · mg–1) was significantly lower than in group II-
C (0.117 ± 0.028 ∆OD · min–1 · mg–1) (P = .044). The inducible nitric oxide
synthase mRNA expression in group II (0.627 ± 0.28) was significantly
lower than in group II-C (1.125 ± 0.63) (P = .039).
Conclusion: Adenovirus-mediated human interleukin 10 gene transfer in vivo
into lung isografts ameliorates subsequent ischemia-reperfusion injury. This
results in improved graft gas exchange, reduced neutrophil sequestration,
and down-regulation of graft inducible nitric oxide synthase mRNA expres-
sion. (J Thorac Cardiovasc Surg 2000;120:947-56)
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L ung transplantation has evolved into an effectivetherapeutic option in the management of patients
with end-stage pulmonary diseases.1 However, early
acute graft dysfunction still remains a serious impedi-
ment to the clinical success of lung transplantation,
accounting for significant postoperative morbidity and
mortality. Temporary introduction of genes to organs
that results in transient gene expression and production
of a functional gene product may be an effective strat-
egy to decrease such ischemia-reperfusion (I/R) injury.
In vivo gene delivery into donor organs before harvest
may offer a specific method for achieving graft-target-
ed, sustained, endogenous production of therapeutic
gene products, while at the same time minimizing pos-
sible unwanted exposure of nontargeted organs. Gene
transfer of anti-inflammatory cytokine genes to the
graft may be a viable local anti-inflammatory strategy,
by impairing inflammatory cytokine cascade or reduc-
ing accumulation of neutrophils into lung grafts after
reperfusion oxidant stress.
Interleukin 10 (IL-10) is mainly produced by
macrophages and helper T lymphocyte 2 cells. It sig-
nificantly modulates expression of cytokines, soluble
mediators, and cell surface molecules on cells of
myeloid origin. IL-10 strongly inhibits the production
of IL-1, IL-6, IL-8, IL-10 itself, IL-12, granulocyte-
macrophage colony-stimulating factor, tumor necrosis
factor α (TNF-α), and various chemokines by activated
monocyte/macrophages.2,3 IL-10 also enhances pro-
duction of IL-1 receptor antagonist2 and soluble p55
and p75 TNF receptor.4 IL-10 also inhibits the expres-
sion of intercellular adhesion molecule-1 (ICAM-1)
and reduces the generation of superoxide anion (O2–)5
and nitric oxide (NO).6 Thus, IL-10 induces a shift
from production of pro-inflammatory to anti-inflam-
matory mediators. Due to these effects, we postulated
that IL-10 may be useful in the treatment or prevention
of I/R injury. In the current study, we examined the
influence of human IL-10 (hIL-10) gene overexpres-
sion in lung isografts on subsequent acute graft dys-
function after orthotopic transplantation.
Material and methods
Adenoviral vectors. The replication-deficient recombinant
adenovirus AdRSVhIL-10 was obtained from the Gene
Therapy Vector Core, University of Iowa, College of
Medicine (Iowa City, Iowa). This recombinant adenovirus
expressing hIL-10 was generated by homologous recombina-
tion between pAdRSVhIL-10 and human adenovirus
serotype 5 derivative d1309, by means of standard methods,7
and the bioactivity of this recombinant adenovirus was con-
firmed by in vitro bioassay, as previously described.8 The
recombinant adenovirus Ad5CMVLacZ expresses the gene
for Escherichia coli β-galactosidase and contains the human
cytomegalovirus gene promoter/enhancer. Adenovirus ampli-
fication was propagated in 293 cells several times to obtain
high-titer stocks, as determined by the plaque assay (Gene
Therapy Center Vector Core Facility, the University of North
Carolina, Chapel Hill, NC). Viral stocks of 1.60 – 3.75 ×
10E11 plaque-forming units per milliliter (pfu/mL) were kept
at –80°C, thawed, and diluted in 1 mL saline solution imme-
diately before intravenous administration to donors.
Animals. Male inbred F344 rats, weighing 250 to 320 g,
were obtained from Harlan Sprague-Dawley Inc
(Indianapolis, Ind). All animal procedures were approved by
the Animal Study Committee of Washington University.
Animals received humane care in compliance with the
“Guide for the Care and Use of Laboratory Animals” pre-
pared by the Institute of Laboratory Animal Resources,
National Research Council, and published by the National
Academy Press, revised 1996.
Study design, gene transfer, and transplantation. Male
F344 rats were divided into 4 groups and underwent left lung
isotransplantation. Twenty-four hours before harvest, 5 ×
10E9 pfu (group I, n = 6) or 1 × 10E10 pfu (group II, n = 7)
of AdRSVhIL-10 was intravenously administered to donor
rats. In groups I-C (n = 6) and II-C (n = 6), serving as control
groups, 5 × 10E9 pfu or 1 × 10E10 pfu of AdCMVLacZ was
administered, respectively. The adenovirus diluted in 1 mL of
saline solution was injected into the left internal jugular vein
of the anesthetized donors in the supine position for 30 sec-
onds, and the donor rats were allowed to recover from anes-
thesia. Twenty-four hours after virus injection, donors were
put to death. Donor lungs were flushed via the main pul-
monary arteries with 20 mL of cold (4°C) low-potassium-
dextran–1% glucose solution after systemic heparinization.
Heart-lung blocks were immediately excised en bloc and
stored in low-potassium-dextran–1% glucose solution at 4°C
for 18 hours. Left lung isografts were then orthotopically
transplanted by means of a modification of the previously
described “cuff technique.”9
Assessment. Recipient animals underwent median ster-
notomy 24 hours after reperfusion. After crossclamping of the
right main bronchus and pulmonary artery, isografts were ven-
tilated with 100% oxygen, 1.5 mL tidal volume, rate 100
breaths/min. Peak airway pressures were measured, and
exhaled gas was collected for 3 minutes. After 5 minutes of
graft ventilation, arterial blood samples were obtained for
blood gas analysis. Recipients were then killed and left lung
isografts were immediately flushed with 20 mL of cold saline
solution. The lower half of the lung graft was frozen in liquid
nitrogen and stored at –80°C for reverse transcriptase–poly-
merase chain reaction (RT-PCR) and myeloperoxidase assess-
ment. The upper half of the graft was fixed with Histochoice
fixative (AMRESCO, Solon, Ohio) flushed through the tra-
chea with 20 cm H2O for immunohistochemistry. 
RNA isolation and cDNA synthesis. Total lung RNA was
prepared by guanidine isothiocyanate extraction with RNeasy
Mini (QIAGEN Inc, Valencia, Calif), according to the manu-
facturer’s instructions. Extracted RNA was quantified by a
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spectrophotometer (Spectronic Genesys 5; Spectronic
Instruments, Inc, Rochester, NY). Each 1 µg of extracted
RNA sample was reverse-transcribed at room temperature for
10 minutes, 42°C for 15 minutes, 99°C for 5 minutes, and
5°C for 5 minutes in a total of 20 µL reaction mixture:
MgCl2, 5 mmol/L; KCl, 50 mmol/L; Tris-HCl, 10 mmol/L;
pH 8.3; and 1 mmol/L of each deoxynucleotide-triphosphate,
1 µL RNase inhibitor, 2.5 U/µL cloned murine leukemia
virus reverse transcriptase, and 2.5 µmol/L oligo d(T)10
(Perkin Elmer, Foster City, Calif).
Semiquantitative PCR. To confirm hIL-10 transfection
and to investigate its influence on isograft cytokine alter-
ation, we performed semiquantitative RT-PCR for transgene
hIL-10 and several endogenous cytokines. Normal left lung
samples of F344 rats (NL, n = 6) were also assayed in the
same way as the other groups for comparison. Reverse-tran-
scribed cDNA was amplified by PCR with 0.02- to 0.03-
U/µL HotStarTaq Polymerase (QIAGEN Inc, Valencia,
Calif) on a Mastercycler gradient (Eppendorf Scientific,
Hamburg, Germany) in a 22-µL reaction: 2.0 µL of reverse
transcriptase product, 1.0 mmol/L of MgCl2, 200 µmol/L of
each deoxynucleotide-triphosphate, and 0.3 to 0.5 µmol/L of
each primer, PCR buffer (QIAGEN Inc, Valencia, Calif)
including KCl, Tris-HCl, (NH4)2SO4, after the first step of
95°C for 17 minutes, 25 to 35 cycles of 95°C for 30 seconds,
58°C (annealing temperature varying for different primers)
for 30 seconds, and 72°C for 1 minute, followed by a final
incubation at 72°C for 10 minutes. The sequence of primer
pairs was designed for glyceraldehyde-3-phosphate dehy-
drogenase (GA3PDH) (sense: 5´-CATGACCACAGTCCAT-
GCCATCAC3´; antisense: 5´-CATGTAGGCCATGAGGTC-
CACCAC-3´; 472 bp), hIL-10 (sense: 5´-CGCGGATCC
CATGCACAGCT CAGCACTG-3´; antisense: 5´-CGCG-
GATCCGCCACCCTGATGTCTCAGT-3´; 570 bp), iNOS
(sense: 5´-GCCTCCCTCTGGAAAGA-3´; antisense: 5´-
TCCATGCAGACAACCTT-3´; 500 bp), TNF-α (sense: 5´-
CTCAAAACTCGAGTGACAAGC-3´; antisense: 5´-
CCGTGATGTCTAAGTACTTGG-3´; 420 bp), growth-
regulated gene product/cytokine-induced neutrophil
chemoattractant-1 (GRO/CINC-1) (sense: 5´-ACTC-
CAACAGAGCACCATGG-3´; antisense: 5´-TTGAGTGTG-
GCTATGACTTCG-3´; 222 bp), monocyte chemotactic pro-
tein-1 (sense: 5´-ATGCAGGTCTCTGTCACG-3´; antisense:
5´-CTAGTTCTCTGTCATACT-3´; 447 bp), and ICAM-1
(sense: 5´-TTCCTGCCTCGGGGTGGATCCG-3´; anti-
sense: 5´-AGAGCTGTGTCCGCGGTGCTCC-3´; 331 bp).
PCR cycles and annealing temperature were calibrated for
each primer pair. The GA3PDH bands were used to calibrate
PCR input at unsaturated amplification for semiquantifica-
tion. PCR products were electrophoresed on a 0.8% agarose
gel and visualized by ethidium bromide staining. The gel
images were stored with the use of the Gel Documentation
System Image Store 7500, version 7.12 (UVP Inc, Upland,
Calif) under an ultraviolet transilluminator. The average
optical density of bands was quantitated by the
GelBase/GelBlot-Pro Version 3.10 (Syngene/Synoptics Ltd,
Frederick, Md).
Immunohistochemistry for hIL-10. Paraffin-embedded
lung isograft sections were mounted on glass slides and per-
meabilized by incubation of the slides in Tris-buffered saline
(TBS) solution (Tris, 100 mmol/L; NaCl, 500 mmol/L; pH
7.4) supplemented with 0.1% saponin and 0.2% Triton X-100
octylphenoxypolyethoxyethanol (Union Carbide Corpor-
ation, Danbury, Conn) according to the protocol of R&D
Systems (Minneapolis, Minn) for cytokine localization. This
buffer was used for all washings. After deparaffinization,
slides were steam-treated in a citrate buffer target retrieval
solution (DAKO Corporation, Carpenteria, Calif) for 35 min-
utes at 95°C. After endogenous peroxidase was blocked with
3% H2O2/phosphate-buffered saline solution for 15 minutes,
slides were incubated in SuperBlock blocking buffer (Pierce
Chemical Company, Rockford, Ill) including 10% normal
goat serum and 1% bovine serum albumin. The immunohis-
tochemistry procedure was performed with a tyramide signal
amplification kit (TSA-Indirect; NEN Life Science Products,
Boston, Mass), according to the manufacturer’s instructions.
In brief, after treatment with trinitrobenzene blocking buffer
in TBS, the slides were incubated overnight at room temper-
ature with 1:25, or 1:12.5-diluted biotinylated rat
antiviral/hIL-10 monoclonal antibody (PharMingen, San
Diego, Calif). After incubation with streptavidin-horseradish
peroxidase for 30 minutes at room temperature, the slides
were incubated in biotinyl tyramide solution for 15 minutes
at room temperature. Then, these incubation steps with strep-
tavidin-horseradish peroxidase and biotinyl tyramide solution
were repeated. After subsequent washes in TBS/Triton X-
100/saponin, the slides were incubated with streptavidin-
alkaline phosphatase for 30 minutes at room temperature.
Color reaction was developed by a BCIP/NBT alkaline phos-
phatase substrate kit (Vector Laboratories, Inc, Burlingame,
Calif) including a 5-mol/L concentration of levamisole. After
about 8 minutes, the reaction field was blocked by washing in
TE buffer (Tris, 10 mmol/L; pH 8.0; ethylenediamine-
tetraacetic acid [EDTA], 1 mmol/L), counterstained with
nuclear fast red, and permanently mounted with Cytoseal 60
(Stephens Scientific, Kalamazoo, Mich).
Myeloperoxydase activity. Quantitative myeloperoxidase
activity was determined as previously described.11 Although
monocyte/macrophages have been shown to produce
myeloperoxidase when activated, the monocyte/macrophage
contribution to the total myeloperoxidase activity is far less
than that of neutrophils because of quantitative predominance
of neutrophils over monocyte/macrophages in peripheral
blood and at sites of acute inflammation. Thus, myeloperox-
idase activity reflects neutrophil sequestration into grafts. In
brief, frozen lung samples were homogenized in 1 mL of
0.5% hexadecyltrimethyl-ammonium bromide, 5 mmol/L
EDTA, and 50 mmol/L potassium phosphate buffer (pH 6.2)
with a Broeck tissue grinder (Kontes Glass Co, Vineland,
NJ). Hexadecyltrimethyl-ammonium bromide is a detergent
that releases myeloperoxidase from the primary granules of
neutrophils. The homogenate was centrifuged at 10,000g for
15 minutes at 4°C. The supernatant was subsequently assayed
for total soluble protein by the method of Pierce Chemical
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Company (Rockford, Ill).12 Myeloperoxidase activity was
measured spectrophotometrically as follows: 2 µL of super-
natant was combined with 0.6 mL Hanks bovine serum albu-
min (0.25% bovine serum albumin added to Hanks solution),
0.5 mL of 100 mmol/L potassium phosphate buffer (pH 6.2),
0.1 mL 0.05% H2O2, and 0.1 mL of 1.25 mg/mL o-diani-
sidine. Color development was stopped by the addition of 0.1
mL of 1% NaN3 after 5 minutes and after 20 minutes at room
temperature. Optical density was measured at 460 nm with a
spectrophotometer (model PMQ II; Carl Zeiss, Jena, West
Germany). Color development was linear from 5 to 20 min-
utes. One unit of enzyme activity was defined as the amount
of 1.0 optical density unit per minute per microgram of tissue
protein at room temperature. Myeloperoxidase activity of
normal left lung of F344 rats (NL, n = 4) was also measured
in the same way as the other groups for comparison. 
Exhaled NO analysis. NO levels in isograft exhaled gas
were measured by a Sievers 280 NO analyzer (Sievers
Instruments, Inc, Boulder, Colo) within 30 minutes of collec-
tion. Emissions from electronically excited nitrogen dioxide
were detected in a gas-phase chemiluminescent reaction
between NO and ozone. The sensitivity of the measurement
is less than 1 ppb. At every measurement, the baseline NO
level of 100% oxygen was confirmed to be 0 ppb. Exhaled
NO from normal left lung of F344 rats (NL, n = 4) was also
measured in the same way as in the other groups.
Statistical analysis. Data were analyzed by 1-way analysis
of variance (ANOVA) and the Fisher post hoc multiple com-
parison test. Data not normally distributed were transformed
with a square root or logarithmic transformation before
ANOVA was performed. All data are expressed as mean ±
standard deviation.
Results
Semiquantitative RT-PCR for transgene hIL-10.
To confirm isograft AdRSVhIL-10 transfection at tran-
scriptional levels, we performed semiquantitative RT-
PCR for transgene hIL-10. Expression of hIL-10
mRNA in lung grafts was detected in all samples of
groups I and II, but not of groups I-C and II-C (Fig 1).
These results confirmed hIL-10 gene transfection into
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Fig 1. Semiquantitative RT-PCR analysis of transgene hIL-10 mRNA expression in rat lung isografts. Peak area of
bands was expressed as a relative ratio of hIL-10/GA3PDH. The gel image shows 570 bp hIL-10 bands in groups
I and II, but not in groups I-C and II-C, showing 4 representatives from each group. Values are mean ± SD of 4 to
6 animals per group.
lung isografts at transcriptional levels in groups I and II
2 days and 18 hours after transfection. 
Immunohistochemistry for transgene hIL-10. To
confirm isograft AdRSVhIL-10 transfection at trans-
lational levels in situ, we performed immunohisto-
chemistry for transgene hIL-10 protein in sections
from paraffin-embedded tissue. Alveolar epithelial
cells, mainly type II cells in a scattered distribution,
and fewer alveolar macrophages showed cytoplasmic
staining (Fig 2). There was no staining in capillary,
large vessel endothelium, or airway epithelial cells.
Staining was specific to transgene hIL-10, since sec-
tions prepared from groups I-C and II-C and normal
lungs (NL) were negative. These findings demonstrat-
ed hIL-10 transfection to specific types of lung cells
and local production of hIL-10 transgene protein in
isografts.
Lung graft function. To investigate the effects of
graft hIL-10 overexpression on isograft lung function,
we compared graft gas exchange and peak airway pres-
sures among groups. Gas exchange remains the single
most important parameter of lung function (Fig 3).
Arterial PO2 (mean mm Hg ± SD) levels in arterial
blood obtained 5 minutes after right hilar crossclamping
in groups I (164.72 ± 85.3) and II (153.19 ± 113) were
significantly higher than in groups I-C (82.37 ± 19.1)
and II-C (77.95 ± 33.4) (P = .022 and P = .031, respec-
tively). Arterial PCO2 (mean mm Hg ± SD) levels in
group I (33.40 ± 6.80) were significantly lower than in
group I-C (51.23 ± 11.9) (P = .0096). There were no
significant differences between groups in peak airway
pressures (P = .24). These data show that graft hIL-10
overexpression significantly improved graft lung func-
tion, suggesting the amelioration of graft I/R injury. 
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Fig 2. Immunohistochemistry for transgene hIL-10. Transgene hIL-10 protein was detected in the sections prepared
from groups I and II as cytoplasmic staining in alveolar epithelial cells, mainly type II cells. There was no staining
in capillary, large vessel endothelium, or airway epithelium. (Original magnifications: A, ×100; B, ×200; C, ×400;
D ×400.)
Myeloperoxidase activity. To investigate hIL-10
effects on neutrophil sequestration into isografts, we
compared myeloperoxidase activity levels among
groups (Fig 4). Myeloperoxidase activity (mean OD ·
min–1 · mg–1 ± SD) in group II (0.083 ± 0.031) was sig-
nificantly lower than in group II-C (0.117 ± 0.028) 
(P = .044). There were no significant differences
between group I (0.124 ± 0.061) and group I-C (0.086
± 0.034) (P = .16). Myeloperoxidase activity in normal
lungs (NL) (0.046 ± 0.013) was significantly lower
than in group I, II, or II-C (P < .05, respectively). These
results suggest that I/R causes significant neutrophil
sequestration into lung grafts and that hIL-10 overex-
pression reduced this sequestration, ameliorating sub-
sequent neutrophil-mediated lung injury.
Semiquantitative RT-PCR for graft cytokine
mRNA expression. To investigate the effects of graft
hIL-10 overexpression on isograft cytokine mRNA
expression at 24 hours of reperfusion, we performed
semiquantitative RT-PCR for graft cytokine mRNA
expression. Levels of iNOS expression (mean relative
units ± SD) in lung grafts in group II (0.627 ± 0.28) were
significantly lower than in group II-C (1.125 ± 0.63) 
(P = .039), whereas normal lung (NL) iNOS expression
(0.097 ± 0.11) was significantly lower than in all other
groups (P < .05, respectively) (Fig 5). There were no sig-
nificant differences between groups I (0.455 ± 0.42) and
I-C (0.755 ± 0.29) (P = .13), indicating that iNOS
mRNA expression level was minimal in normal lung and
up-regulated in graft I/R injury by 24 hours after reper-
fusion. The iNOS mRNA up-regulation was significant-
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Fig 3. A, PaO2 of blood obtained 5 minutes after right hilar
crossclamping. Each PaO2 in groups I (164.72 ± 85.3 mm Hg)
and II (153.19 ± 113 mm Hg) was significantly higher than in
groups I-C (82.37 ± 19.1 mm Hg) and II-C (77.95 ± 33.4 mm
Hg) (P = .022 and .031, respectively, ANOVA). Values are
mean ± SD of 6 to 7 animals per group. B, PaCO2 of blood
obtained 5 minutes after right hilar crossclamping. PaCO2 in
group I (33.40 ± 6.80 mm Hg) was significantly lower than in
group I-C (51.23 ± 11.9 mm Hg) (P = .0096, ANOVA). There
were no significant differences between groups II (43.64 ±
15.1 mm Hg) and II-C (50.6 ± 17.7 mm Hg) (P = .46,
ANOVA). Values are mean ± SD of 6 to 7 animals per group.
A
B
Fig 4. Myeloperoxidase (MPO) activity in rat lung isografts.
Myeloperoxidase activity in group II (0.083 ± 0.031 OD ·
min–1 · mg–1) was significantly lower than in group II-C
(0.117 ± 0.028 OD · min–1 · mg–1) (P = .044, ANOVA). There
were no significant differences between groups I (0.124 ±
0.061 OD · min–1 · mg–1) and I-C (0.086 ± 0.034 OD · min–1
· mg–1) (P = .16, ANOVA). Values are mean ± SD of 4 to 6
animals per group. Myeloperoxidase activity in normal lung
(NL) was significantly lower than groups I, II, and II-C (*P <
.05, respectively, ANOVA).
ly suppressed only by high amounts of graft hIL-10
transfection. Normal lung mRNA expression of TNF-α
and monocyte chemotactic protein-1 was significantly
lower than in all other groups (P < .05, respectively),
although there were no significant differences between
groups I and I-C or groups II and II-C. There were no
significant differences among groups in GRO/CINC-1
and ICAM-1 mRNA expression levels (P = .33 and 
P = .31, respectively) (Fig 6).
Exhaled NO levels. To investigate hIL-10 effects on
exhaled NO levels of isografts, we compared exhaled
NO levels at 24 hours of reperfusion between groups.
There were no significant differences between groups
in exhaled NO levels (P = .25); exhaled NO levels
(mean ppb ± SD) in groups I (6.525 ± 6.61), I-C (3.133
± 4.01), II (6.357 ± 5.93), II-C (3.033 ± 4.60), and nor-
mal left lungs (NL) of F344 rats (0.00 ± 0.0) are given
in Fig 7. 
Comment
The present data show that overexpression of hIL-10
in lung isografts by means of donor in vivo adenovirus-
mediated gene transfer improved gas exchange,
reduced lung neutrophil sequestration, and down-regu-
lated local iNOS mRNA expression 24 hours after graft
reperfusion. During the initial phase of lung I/R injury,
pulmonary resident macrophages are activated and
release reactive oxygen species and pro-inflammatory
cytokines, including TNF-α and IL-1.13 The enhanced
production of TNF-α and IL-1 plays a central role in
the initiation of a cascade of events including the
recruitment of neutrophils that causes significant lung
graft injury. One of the main functions of TNF-α and
IL-1 is the up-regulation of adhesion molecules14 and
neutrophil-attracting CXC chemokines.15 The coordi-
nated efforts of adhesion molecules and CXC
chemokines mediate the recruitment of neutrophils into
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Fig 5. Semiquantitative RT-PCR analysis of iNOS mRNA expression in rat lung isografts. Peak area of bands was
expressed as relative ratio of iNOS/GA3PDH. iNOS mRNA expression in group II (0.627 ± 0.28) was significant-
ly lower than group II-C (1.125 ± 0.63) (P = .039, ANOVA). iNOS mRNA expression in normal lung (NL) (0.097
± 0.11) was significantly lower than other groups (*P < .05, respectively, ANOVA). Values are mean ± SD of 6 to
7 animals per group.
lung grafts. Sequestrated, activated neutrophils may be
one of the primary effector cells that mediate acute
lung graft injury through the release of a variety of
inflammatory mediators, including proteolytic
enzymes and reactive oxygen species. According to
various in vitro studies, IL-10 can suppress
macrophage function with the production of TNF-α,
IL-1,2,3 several chemokines, ICAM-1,16 and superox-
ide anion,5 which are closely involved in organ I/R
injury. It has been also reported that IL-10 inhibits neu-
trophil function, including cytokine/chemokine pro-
duction10 and the generation of free radicals.17 Recent
in vivo studies have also suggested a protective role for
IL-10 during lung I/R injury in the rat,18 intestinal I/R
injury in the mouse,19 or immune complex–induced
lung injury in the rat.20 Consistent with these reports,
the present results showed that IL-10 overexpression
ameliorates I/R injury, suggesting a cumulative effect
of its various anti-inflammatory functions at crucial
steps of the above-mentioned lung I/R injury cascade.
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Fig 6.  Semiquantitative RT-PCR analysis for mRNA expression of TNF-α, monocyte chemotactic protein-1
(MCP-1), ICAM-1, and GRO/CINC-1 in rat lung isografts. Normal lung (NL) mRNA expression in TNF-α and
monocyte chemotactic protein-1 were significantly lower than other groups (*P < .05, respectively, ANOVA).
There were no significant differences between groups in ICAM-1 and GRO/CINC-1. Values are mean ± SD of 4
to 7 animals per group. 
Fig 7. Exhaled NO levels (ppb) from rat lung isografts.
There were no significant differences between groups (P =
.25, ANOVA). Values are mean ± SD of 4 to 7 animals per
group. 
The present results showed that graft overexpression
of hIL-10 suppresses local iNOS expression, with
simultaneous attenuation of the net isograft I/R injury.
Several reports of iNOS suppression by IL-106 support
these results. Although NO is thought to play a crucial
role in lung I/R injury, its net effect on lung I/R injury
remains unclear, depending on the fine balance
between its toxicity on one hand and its salutary action
on the other. In a canine lung transplant model, nitro-
prusside (NO donor) significantly improved gas
exchange and prevented neutrophil sequestration in
lungs.21 NO inhalation has been also advocated as a
means of selectively reducing pulmonary hypertension
and improving ventilation/perfusion mismatching in
patients with adult respiratory distress syndrome.22 NO
has been shown to cause smooth muscle relaxation (by
activating soluble guanylate cyclase) and to inhibit
platelet aggregation and adhesion to the endothelium
(by increasing cyclic guanosine monophosphate). The
potential role of NO as a cytotoxic effector molecule
may, on the other hand, contribute to lung I/R injury
through inactivation of critical iron-containing
enzymes, such as complexes I and II of the respiratory
chain23 or a radical-radical reaction with superoxide to
yield peroxynitrite anion (ONOO-), a potent oxidizing
cytotoxic molecule.24 It has been shown that NO syn-
thase inhibitors caused the limited neutrophil accumu-
lation and vascular protein leakage in postischemic
lung and skeletal muscle in rats.25 Noiri and associ-
ates26 have also shown that targeted inhibition of iNOS
with antisense oligodeoxynucleotide attenuated
ischemia-induced renal dysfunction in rats. Put into the
context of these studies, our data imply that lung graft
I/R injury is at least partially mediated by up-regulation
of iNOS. IL-10 may attenuate lung I/R injury by sup-
pressing NO-driven injury. The precise relationship
between lung I/R injury and NO is not yet clear.
In the present study, adenovirus vectors were intra-
venously administered to donors 24 hours before har-
vest. Serotype 2 and 5 recombinant adenovirus vectors
are trophic to the respiratory tract and have been the
most widely used vectors for gene transfer to the lung.
Several in vivo studies have demonstrated its biodistri-
bution, clearance, or time-course of transgene expres-
sion after intravenous administration. Intravenous
administration of the adenovirus vectors delivers the
vast majority of the input virus to the liver.27 More than
90% of the administered vector is also eliminated from
the body within 24 hours of administration, well before
maximal levels of transgene are expressed.28 Only a
small percentage of the input adenovirus vector, there-
fore, is responsible for subsequent transgene expres-
sion found in lungs. One study reported that gene
expression after intratracheal AdRSVLacZ transfection
peaked on day 5 and was sustained over a 21- to 28-day
period.29 This pattern of transgene expression seems
suitable for achieving adenovirus hIL-10 transgene
expression at the time of isograft reperfusion with the
present incubation and storage time. Using AdHSP-70,
we30 have previously shown that the same dose and
timing of adenovirus administration and har-
vest/preservation produced transgene expression at
reperfusion and decreased reperfusion injury.
In this experiment, immunohistochemistry for trans-
gene hIL-10 demonstrated predominant cytoplasmic
staining of alveolar epithelial cells, mainly type II cells.
Several studies of acute wild-type adenoviral respirato-
ry infection have shown that there is a histologic pat-
tern with predominant involvement of pneumocytes
over other bronchial epithelial cells.31 When aden-
ovirus enters into the cells, several variables potential-
ly can play a role in the cell-type affinity of adenovirus
vectors; that is, densities of fiber knob receptor and
integrins on the cell surface, differential rate of endo-
cytosis, and electrostatic repulsion by the negative
charge of both adenovirus and cells.32 Taken together,
it is conceivable that type II alveolar epithelial cells
have relatively more affinity to adenovirus vectors than
endothelial or bronchial epithelial cells. This is consis-
tent with the present immunohistochemistry result.
Although we have previously demonstrated a posi-
tive correlation between iNOS mRNA expression and
exhaled NO levels in a rat lung allograft rejection
model, increased iNOS mRNA levels in lung isografts
at 24 hours of reperfusion did not correlate positively to
exhaled NO levels in the current study. There has been
one report demonstrating that the exhaled NO levels
were acutely up-regulated and returned to baseline over
several minutes after hydrochloric acid–induced canine
lung injury.33 In this report, increased nitrite/nitrate lev-
els in the bronchoalveolar lavage fluid 4 hours after
lung injury suggested that iNOS and NO are up-regu-
lated but cannot be reflected by exhaled NO levels. It is
possible that massive alveolar exudate in the severely
injured lung grafts, as is in our present study, played a
role like a sink for NO preventing its measurement by
the exhaled route.
In conclusion, the present study demonstrated that
overexpression of hIL-10 in lung isografts by means of
donor in vivo adenovirus-mediated gene transfer amel-
iorates I/R injury, causing improved gas exchange,
reduced lung neutrophil sequestration, and down-regu-
lation of local iNOS mRNA expression. These results
suggest the therapeutic potential of graft IL-10 gene
transfer as an effective strategy against acute graft dys-
function after lung transplantation.
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